{
    "ticker": "ERNA",
    "name": "Erasca, Inc.",
    "description": "Erasca, Inc. is a clinical-stage biopharmaceutical company dedicated to delivering innovative therapies for patients with cancer. Founded in 2018, the company focuses on developing targeted therapies that address the underlying mechanisms of cancer, with an emphasis on personalized medicine. Erasca\u2019s pipeline includes a diverse range of investigational drugs aimed at treating various types of cancers, including those with specific genetic mutations. The company's lead product candidates are designed to inhibit critical oncogenic pathways, offering patients more effective treatment options with potentially fewer side effects compared to traditional chemotherapy. Erasca is committed to advancing cancer research and improving patient outcomes through collaboration with leading academic institutions and research organizations. By leveraging cutting-edge science and technology, Erasca aims to transform the treatment landscape for patients with difficult-to-treat cancers. The company\u2019s mission is to provide hope and therapeutic solutions to patients and their families affected by cancer, thereby making a meaningful impact on the lives of individuals battling this disease.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "San Diego, California, USA",
    "founded": "2018",
    "website": "https://www.erasca.com",
    "ceo": "Jackie F. H. Hsu",
    "social_media": {
        "twitter": "https://twitter.com/ErascaInc",
        "linkedin": "https://www.linkedin.com/company/erasca/"
    },
    "investor_relations": "https://investors.erasca.com",
    "key_executives": [
        {
            "name": "Jackie F. H. Hsu",
            "position": "CEO"
        },
        {
            "name": "Charles S. E. J. B. Hsu",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Oncology Therapies",
            "products": [
                "ERAS-007",
                "ERAS-001"
            ]
        }
    ],
    "seo": {
        "meta_title": "Erasca, Inc. | Innovative Cancer Therapies",
        "meta_description": "Learn about Erasca, Inc., a biopharmaceutical company focused on developing targeted cancer therapies. Explore our pipeline and mission to improve cancer treatment.",
        "keywords": [
            "Erasca",
            "Cancer Therapy",
            "Biopharmaceuticals",
            "Oncology",
            "Targeted Therapy",
            "Clinical Trials"
        ]
    },
    "faq": [
        {
            "question": "What is Erasca known for?",
            "answer": "Erasca is known for developing innovative targeted therapies for cancer treatment."
        },
        {
            "question": "Who is the CEO of Erasca?",
            "answer": "Jackie F. H. Hsu is the CEO of Erasca, Inc."
        },
        {
            "question": "Where is Erasca headquartered?",
            "answer": "Erasca is headquartered in San Diego, California, USA."
        },
        {
            "question": "What are Erasca's main products?",
            "answer": "Erasca's main product candidates include ERAS-007 and ERAS-001, targeting specific cancer pathways."
        },
        {
            "question": "When was Erasca founded?",
            "answer": "Erasca was founded in 2018."
        }
    ],
    "competitors": [
        "BMY",
        "AMGN",
        "MRNA",
        "REGN"
    ],
    "related_stocks": [
        "ABBV",
        "JNJ",
        "PFE",
        "GILD"
    ]
}